Open AccessMeðferð lifrarbólgu C með peg-interferóni og ríbavíríni á Íslandi 2002-2012
Author(s) -
Benedikt Fridriksson,
Ottar M. Bergmann,
Sigurður Ólafsson
Publication year - 2017
Publication title -
læknablaðið
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.147
H-Index - 12
eISSN - 1670-4959
pISSN - 0023-7213
DOI - 10.17992/lbl.2017.03.126
Subject(s) - medicine , cirrhosis , ribavirin , genotype , gastroenterology , pegylated interferon , genotyping , hepatitis c virus , hepatitis c , population , sofosbuvir , immunology , virus , biology , biochemistry , environmental health , gene
Hepatitis C is a major cause of chronic liver disease and cirrhosis in Western countries. Its treatment aims at eradicating the virus and patients are considered cured if the virus is undetectable by PCR in blood 12-24 weeks after end of treatment (sustained virological response, SVR). The aim of this study is to investigate the results of treating hepatitis C in Iceland during the period 2002-2012.